gene

C1Q

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about C1Q: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1565Connections

8Hypotheses

27Analyses

50Outgoing

50Incoming

7Experiments

Summary

C1Q is a gene implicated in neurodegeneration research. Key relationships include: activates, associated with, interacts with. Associated with AD, ALI, ALS. Connected to 856 entities in the SciDEX knowledge graph.

View on Wiki →

🧬 Gene Info

Gene Symbol	C1Q
Full Name	c1q
Protein Type	Signaling Protein
Target Class	Signaling Protein
Function	Complement cascade inhibitor or antibody-mediated neutralization
Mechanism of Action	Complement cascade inhibitor or antibody-mediated neutralization
Primary Expression	Primarily expressed in myeloid cells (monocytes, macrophages, microglia); astrocytic expression detected in disease states
Subcellular Localization	synapses, dystrophic neurites, extracellular protein aggregates, and vascular interfaces. These features make C1QA a hig
Druggability	Low (0.36)
Clinical Stage	Approved
Molecular Weight	26 kDa
Pathways	Chaperone, Complement, Differentiation, Endocytosis, Epigenetic
UniProt ID	P02745
NCBI Gene ID	712
Ensembl ID	ENSG00000173372
GeneCards	C1Q
Human Protein Atlas	C1Q
Associated Diseases	A1 Astrocytes, A1 Reactive Astrocytes, AD, AGING, ALI, AML
Known Drugs/Compounds	RAPAMYCIN, Beta-Amyloid Oligomers, β-amyloid Oligomers, rapamycin, β-Amyloid Oligomers, LPS
Interactions	C3, C1QA, C1QC, RAB11, RAB5, CNTNAP4
SciDEX Target	View Target Profile (4 clinical trials)
KG Connections	1545 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: C1Q — AlphaFold P02745 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    C1Q["C1Q"] -->|"associated"| neurodegeneration["neurodegeneration"]
    C1Q["C1Q"] -->|"interacts"| C3["C3"]
    C1Q["C1Q"] -->|"co discussed"| NAMPT["NAMPT"]
    C1Q["C1Q"] -->|"co discussed"| GPX4["GPX4"]
    C1Q["C1Q"] -->|"co discussed"| PLA2G6["PLA2G6"]
    C1Q["C1Q"] -->|"co discussed"| MMP2["MMP2"]
    C3_1["C3"] -->|"interacts"| C1Q["C1Q"]
    MMP9["MMP9"] -->|"co discussed"| C1Q["C1Q"]
    SLC7A11["SLC7A11"] -->|"co discussed"| C1Q["C1Q"]
    AQP4["AQP4"] -->|"co discussed"| C1Q["C1Q"]
    style C1Q fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (1117)

Target	Relation	Type	Str
CR3	signals_through	receptor	1.00
MICROGLIA	activates	cell_type	1.00
PHAGOCYTOSIS	activates	phenotype	1.00
Complement	activates	pathway	1.00
Als	associated_with	disease	1.00
Synapse Loss	mediates	phenotype	0.95
A1 Astrocytes	associated_with	phenotype	0.95
Trained Immunity	modulates	process	0.95
Microglial Phagocytosis	mediates	process	0.95
Reactive Astrocytes	activates	cell_type	0.95
A1 Reactive Astrocytes	associated_with	phenotype	0.95
C3-Cr3 Signaling Pathway	activates	pathway	0.95
Tumor-Associated Macrophages	expressed_in	cell_type	0.95
Inflammation	activates	disease	0.95
Alzheimer	activates	disease	0.95
Tumor	associated_with	disease	0.95
Atherosclerosis	risk_factor_for	disease	0.95
ATHEROSCLEROSIS	associated_with	entity	0.95
Alzheimer's Disease	mediates	disease	0.95
Alzheimer'S Disease	involved_in	disease	0.92
immunosuppression	causes	phenotype	0.90
synaptic dysfunction	causes	phenotype	0.90
A1 reactive astrocytes	activates	cell_type	0.90
Human Atherosclerotic Plaques	involved_in	phenotype	0.90
Microglial Synapse Engulfment	mediates	process	0.90
Synapse Loss	associated_with	phenotype	0.90
Classical Complement Cascade	activates	pathway	0.90
β-Amyloid Oligomer Toxicity	associated_with	mechanism	0.90
Synapse Elimination	mediates	process	0.90
Myeloid Cell Metabolism	associated_with	process	0.90
Microglial Synapse Engulfment	activates	process	0.90
Human Atherosclerotic Plaques	associated_with	disease	0.90
Microglial Phagocytosis Of Synapses	regulates	process	0.90
Synapse Loss	promotes	phenotype	0.90
ISCHEMIC STROKE	associated_with	entity	0.90
NEUROINFLAMMATION	mediates	entity	0.90
Phagocytosis	activates	pathway	0.90
Complement	inhibits	pathway	0.90
Inflammatory Reactivity	inhibits	phenotype	0.88
Beta-Amyloid Oligomers	interacts_with	compound	0.88
SYNAPSE_ELIMINATION	regulates	phenotype	0.87
Synaptic Tagging	mediates	process	0.85
Ischemic Stroke	associated_with	disease	0.85
Large Artery Atherosclerosis	biomarker_for	disease	0.85
Synaptic Pruning	involved_in	process	0.85
Synaptic Pruning	involved_in	process	0.85
Excitatory Synapse Elimination	involved_in	process	0.85
Inhibitory Synapse Elimination	involved_in	process	0.85
NEUROCOGNITIVE DYSFUNCTION	contributes_to	entity	0.85
Atherosclerotic Plaques	associated_with	structure	0.85

Incoming (448)

Source	Relation	Type	Str
COMPLEMENT	activates	gene	1.00
MICROGLIA	associated_with	gene	1.00
ALZHEIMER'S DISEASE	associated_with	disease	1.00
NPTX2	binds	protein	0.95
TYROBP deficiency	inhibits	phenotype	0.90
SPP1	upregulates	entity	0.90
NEURODEGENERATION	associated_with	gene	0.90
h-58e4635a	targets_gene	hypothesis	0.90
h-89500d80	targets_gene	hypothesis	0.90
β-Amyloid Oligomers	interacts_with	compound	0.85
TYROBP	regulates	protein	0.85
MICROGLIA	inhibits	gene	0.82
AMYLOID	associated_with	gene	0.82
STAT6-MafB pathway	contributes_to	pathway	0.80
h-58e4635a	targets	hypothesis	0.80
CD2AP	correlates_with	protein	0.80
SDA-2026-04-01-gap-013	targets	analysis	0.80
OCULAR HYPERTENSION	upregulates	biological_process	0.80
microglia	produces	cell_type	0.80
ABETA	upregulates	protein	0.80
MICROGLIA	secretes	cell_type	0.80
COMPLEMENT	regulates	gene	0.80
COMPLEMENT	inhibits	gene	0.80
ALZHEIMER	activates	gene	0.80
Microglia	associated_with	cell_type	0.75
Astrocytes	associated_with	cell_type	0.75
MICROGLIA	activates	cell_type	0.74
ASTROCYTES	associated_with	gene	0.74
NPTX2	interacts_with	protein	0.72
MICROGLIA	expressed_in	cell_type	0.72
oxidized lipids	activates	process	0.70
APOE	interacts_with	protein	0.70
periodontal infection	activates	disease	0.70
ocular hypertension	activates	disease	0.70
retinal ischemia/reperfusion injury	activates	process	0.70
C1QA	activates	gene	0.70
TAU	activates	gene	0.70
APOE	co_mentioned_with	gene	0.70
COMPLEMENT	biomarker_for	gene	0.70
NEURODEGENERATION	activates	gene	0.70
COMPLEMENT	associated_with	gene	0.70
CYTOKINES	activates	gene	0.70
COMPLEMENT	interacts_with	gene	0.70
NEURODEGENERATION	regulates	gene	0.70
AMYLOID	activates	gene	0.70
ALZHEIMER	regulates	gene	0.70
NEURODEGENERATIVE DISEASES	causes	gene	0.70
NEURODEGENERATIVE DISORDERS	activates	gene	0.70
NEURODEGENERATIVE DISEASES	activates	gene	0.70
h-89500d80	targets	hypothesis	0.70

Targeting Hypotheses (8)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Complement C1q Suppression as Mechanism Linking Exercise Pla	0.560	neurodegeneration	What are the specific circulating factor
TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimina	0.520	neurodegeneration	How do the seven novel ALS genes functio
C1QA/C1QB Subunit-Specific Inhibition to Block Aberrant PV I	0.497	neurodegeneration	Are interneuron oscillation deficits com
Complement C1q Mimetic Decoy Therapy	0.479	neurodegeneration	Synaptic pruning by microglia in early A
Complement C1QA Inhibition Synergizes with PV Interneuron Mo	0.473	neurodegeneration	What molecular mechanisms underlie the d

C1q Inhibition Prevents Synaptic Mitochondrial Dysfunction v	0.455	neurodegeneration	Why does PRKN-mediated mitophagy, typica
Complement C1q Subtype Switching	0.437	neurodegeneration	4R-tau strain-specific spreading pattern
Complement C1QA Spatial Gradient in Cortical Layers	0.428	Alzheimer's Disease	SEA-AD Gene Expression Profiling — Allen

Mentioning Analyses (27)

Scientific analyses that reference this entity

Experiments (7)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Bidirectional Mendelian randomization analysis of C1Q and ischemic str	exploratory	Ischemic stroke, Atheroscleros	0.900	0.00	Human genetic association data	proposed	N/A
Bidirectional Mendelian randomization analysis of C1Q and ischemic str	exploratory	Ischemic stroke (large artery	0.900	0.00	human genetic data	proposed	N/A
Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxic	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Experiment: Autoimmune Hypothesis Testing in AD	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
cGAS-STING Pathway Validation Study in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,100,000
s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin	falsification	Neuroinflammation	0.400	0.50	mouse	proposed	$200,000
Proposed experiment from debate on Synaptic pruning by microglia in ea	falsification	Alzheimer's Disease	0.400	0.50	mouse	proposed	$200,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Prolonged anesthesia induces neuroinflammation and complement-mediated microglia [PMID:36600274]	Xu F, Han L, Wang Y, Deng D, Ding Y, Zha	BMC Med	2023	2
Perivascular cells induce microglial phagocytic states and synaptic engulfment v [PMID:36747024]	De Schepper S, Ge JZ, Sierksma A, Crowle	Nat Neurosci	2023	2
An integrative analysis of single-cell and bulk transcriptome and bidirectional [PMID:38179058]	Cui HK, Tang CJ, Gao Y, Li ZA, Zhang J,	Front Immunol	2023	2
Early complement genes are associated with visual system degeneration in multipl [PMID:31289819]	Fitzgerald KC, Kim K, Smith MD, Aston SA	Brain	2019	1
Phosphoproteomics uncovers a neuroimmune perspective on trigeminal neuralgia: se [PMID:41853292]	Zhai X, Lin X, Zhang L, Ren Y, Miao H, M	Frontiers in immunology	2026	0
Proteomic Signature in Men with Central Serous Chorioretinopathy. [PMID:41641862]	Chambon C, Picard E, Zola M, Aichedo S,	Journal of proteome research	2026	0
Machine Learning and Blood-Targeted Proteomics Enable Early Prediction and Etiol [PMID:41683823]	Starodubtseva N, Tokareva A, Kononikhin	International journal of molec	2026	0
Club cell RhoA activation amplifies allergic airway inflammation by regulating e [PMID:41633491]	Tu W, Wu M, Wan R, Alphonse M, Gu W, Gho	The Journal of allergy and cli	2026	0
Identifying the hub genes in macrophage infiltration and verifying of the role o [PMID:41730938]	Tang L, Xu Y, Nong Z, Li F, Pan L	Scientific reports	2026	0
Molecular Insights Into Canine Hepatocellular Carcinoma: A Cross-Species Transcr [PMID:41664952]	Arif M, Hasan MN, Nozaki N, Ide Y, Akiya	Mol Carcinog	2026	0
Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746]	["Sanadgol N", "Abedi M", "Hashemzaei M"	Journal of nanobiotechnology	2025	0
The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and resc [PMID:39129007]	Chae S, Lee HJ, Lee HE, Kim J, Jeong YJ,	Journal of neuroinflammation	2024	0
Identification of crosstalk genes and immune characteristics between Alzheimer's [PMID:39188714]	An W, Zhou J, Qiu Z, Wang P, Han X, Chen	Frontiers in immunology	2024	0
Single-cell RNA sequencing reveals distinct immunology profiles in human keloid. [PMID:35990663]	["Feng C", "Shan M", "Xia Y", "Zheng Z",	Frontiers in immunology	2022	0
Evaluation method for cell-free in situ tissue-engineered vasculature monitoring [PMID:35436313]	["Matsumura G", "Isayama N", "Sato H"]	PloS one	2022	0
Evidence that ageing yields improvements as well as declines across attention an [PMID:34413509]	["Ver\u00edssimo J", "Verhaeghen P", "Go	Nature human behaviour	2022	0
[WALANT - Wide Awake Local Anaesthesia No Tourniquet: Complications in elective [PMID:35168268]	Wieschollek S, Forster S, Megerle K	Handchirurgie, Mikrochirurgie,	2022	0
Complement factor C1q mediates sleep spindle loss and epileptic spikes after mil [PMID:34516796]	Holden SS, Grandi FC, Aboubakr O, Higash	Science (New York, N.Y.)	2021	0
Adaptive learning algorithms to optimize mobile applications for behavioral heal [PMID:33657217]	Figueroa CA, Aguilera A, Chakraborty B,	Journal of the American Medica	2021	0
Engineering complex communities by directed evolution. [PMID:33986540]	Chang CY, Vila JCC, Bender M, Li R, Mank	Nature ecology & evolution	2021	0

C1Q

Understanding Entity Pages

Summary

Wiki Pages (21)

C1QA Gene — Complement Component 1q A Chain

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

Microglia CD8+ T Cell Recruitment -- Supplementary WW Content

Atypical Parkinsonism

PD Combination Therapy Matrix

neuroinflammation

Microglial Cells — Cell Type Hierarchy

Neuroimmune Response in 4R-Tauopathies: Cross-Disease Comparison

Astrocyte Reactivity Mechanism

TREM2 Microglial Signaling Pathway in Neurodegeneration

dendritic-spines

cognitive-reserve-cbs-psp

Glia-Neuron Crosstalk in Alzheimer's Disease

Synucleinopathies

Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)

Astrocytes

Section 153: Virtual Reality Therapy Protocols in CBS/PSP

Microglial Senescence Pathway in Neurodegeneration

Synaptic Dysfunction in Neurodegeneration

Pathway Diagram

Outgoing (1117)

Incoming (448)

Targeting Hypotheses (8)

Mentioning Analyses (27)

Why does PRKN-mediated mitophagy, typically protective, cause harmful mitochondr

Is C1q elevation in AD pathogenic or compensatory for amyloid clearance?

Can pathological vs physiological C1q tagging be distinguished at the molecular

Do these mechanistic hypotheses from the SEA-AD Atlas bundle explain layer-speci

Do these mechanistic hypotheses explain layer-specific synaptic vulnerability in

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

How does SPI1 transcriptionally regulate C1QA and C1QC expression in atheroscler

How does sevoflurane-induced NF-κB activation specifically trigger complement ca

What determines the selectivity of complement-mediated synaptic elimination in p

What are the specific molecular mechanisms by which C1Q components drive atheros

Epigenetic reprogramming in aging neurons

Neuroinflammation and microglial priming in early Alzheimer's Disease

Tau propagation mechanisms and therapeutic interception points

Which cell types show the most significant expression changes for neurodegenerat

Gene expression changes in aging mouse brain predicting neurodegenerative vulner

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

Epigenetic clocks and biological aging in neurodegeneration

Mitochondrial transfer between astrocytes and neurons

RNA binding protein dysregulation across ALS FTD and AD

Synaptic pruning by microglia in early AD

Senolytic therapy for age-related neurodegeneration

Autophagy-lysosome pathway convergence across neurodegenerative diseases

Microglia-astrocyte crosstalk amplification loops in neurodegeneration

Astrocyte reactivity subtypes in neurodegeneration

4R-tau strain-specific spreading patterns in PSP vs CBD

Blood-brain barrier transport mechanisms for antibody therapeutics

Mechanistic role of APOE in neurodegeneration

Experiments (7)

Related Papers (20)